
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8273388/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Morphine-3-glucuronide - a potent antagonist of morphine analgesia. Life Sciences, 1990, 47, 579-585.	4.3	307
2	The pharmacokinetics of midazolam in man. European Journal of Clinical Pharmacology, 1981, 19, 271-278.	1.9	266
3	Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. Journal of Critical Care, 2012, 27, 741.e9-741.e18.	2.2	257
4	Neuroexcitatory Effects Of Morphine And Hydromorphone: Evidence Implicating The 3-Glucuronide Metabolites. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 524-528.	1.9	255
5	Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading. Frontiers in Pharmacology, 2016, 7, 185.	3.5	255
6	Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Critical Care, 2012, 16, R194.	5.8	233
7	The intrinsic antinociceptive effects of oxycodone appear to be $\hat{I}^2$ -opioid receptor mediated. Pain, 1997, 73, 151-157.	4.2	228
8	Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Frontiers in Pharmacology, 2013, 4, 156.	3.5	204
9	The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung and Circulation, 2003, 12, 44-50.	0.4	173
10	The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain, 2002, 96, 119-127.	4.2	155
11	PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. British Journal of Cancer, 2011, 104, 635-642.	6.4	154
12	Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain, 2007, 132, 289-300.	4.2	149
13	Neurotrophins and Neuropathic Pain: Role in Pathobiology. Molecules, 2015, 20, 10657-10688.	3.8	145
14	Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clinical Pharmacology and Therapeutics, 1992, 52, 487-495.	4.7	136
15	Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. Angewandte Chemie - International Edition, 2016, 55, 3580-3585.	13.8	126
16	Hydromorphone-3-glucuronide. Life Sciences, 2001, 69, 409-420.	4.3	119
17	Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Pain, 1995, 62, 51-60.	4.2	107
18	Dose-dependent pharmacokinetics of caffeine in humans: Relevance as a test of quantitative liver function. Clinical Pharmacology and Therapeutics, 1990, 47, 516-524.	4.7	99

#	Article	IF	CITATIONS
19	Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. Inflammopharmacology, 2014, 22, 1-22.	3.9	98
20	An Update on the Pharmacological Management of Post-Herpetic Neuralgia and Painful Diabetic Neuropathy. CNS Drugs, 2008, 22, 417-442.	5.9	97
21	Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology, 2018, 131, 238-255.	4.1	97
22	The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sciences, 1994, 54, 687-694.	4.3	91
23	ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiology, 2012, 12, 29.	1.8	90
24	Pharmacokinetics and Pharmacodynamics of Oxycodone When Given Intravenously and Rectally to Adult Patients with Cancer Pain. Anesthesia and Analgesia, 1995, 80, 296-302.	2.2	87
25	A Randomized, Controlled Trial of Oxycodone Versus Placebo in Patients With PostHerpetic Neuralgia and Painful Diabetic Neuropathy Treated With Pregabalin. Journal of Pain, 2010, 11, 462-471.	1.4	85
26	Small Molecule Angiotensin II Type 2 Receptor (AT <sub>2</sub> R) Antagonists as Novel Analgesics for Neuropathic Pain: Comparative Pharmacokinetics, Radioligand Binding, and Efficacy in Rats. Pain Medicine, 2013, 14, 692-705.	1.9	79
27	Anti-allodynic efficacy of the χ-conopeptide, Xen2174, in rats with neuropathic pain. Pain, 2005, 118, 112-124.	4.2	78
28	Comparative Oxycodone Pharmacokinetics in Humans After Intravenous, Oral, and Rectal Administration. Therapeutic Drug Monitoring, 1992, 14, 479-484.	2.0	75
29	Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain, 2000, 84, 421-428.	4.2	75
30	Pregabalin in severe burn injury pain: A double-blind, randomised placebo-controlled trial. Pain, 2011, 152, 1279-1288.	4.2	74
31	Synthesis and Biological Evaluation of an Orally Active Glycosylated Endomorphin-1. Journal of Medicinal Chemistry, 2012, 55, 5859-5867.	6.4	72
32	χ-Conopeptide Pharmacophore Development: Toward a Novel Class of Norepinephrine Transporter Inhibitor (Xen2174) for Pain. Journal of Medicinal Chemistry, 2009, 52, 6991-7002.	6.4	70
33	A Small Molecule Angiotensin II Type 2 Receptor (AT <sub>2</sub> R) Antagonist Produces Analgesia in a Rat Model of Neuropathic Pain by Inhibition of p38 Mitogen-Activated Protein Kinase (MAPK) and p44/p42 MAPK Activation in the Dorsal Root Ganglia. Pain Medicine, 2013, 14, 1557-1568.	1.9	66
34	Sensory changes during the ovulatory phase of the menstrual cycle in healthy women. European Journal of Pain, 2001, 5, 135-144.	2.8	65
35	Pharmacology of Morphine and Morphineâ€3â€glucuronide at Opioid, Excitatory Amino Acid, GABA and Glycine Binding Sites. Basic and Clinical Pharmacology and Toxicology, 1994, 75, 73-81.	0.0	62
36	Pharmacological inhibition of the NLRP3 inflammasome as a potential target for multiple sclerosis induced central neuropathic pain. Inflammopharmacology, 2018, 26, 77-86.	3.9	62

#	Article	IF	CITATIONS
37	Morphine-3-Glucuronide's Neuro-Excitatory Effects Are Mediated via Indirect Activation of N-Methyl-d-Aspartic Acid Receptors: Mechanistic Studies in Embryonic Cultured Hippocampal Neurones. Anesthesia and Analgesia, 2003, 97, 494-505.	2.2	61
38	Pharmacokinetics of midazolam in the aged. European Journal of Clinical Pharmacology, 1984, 26, 381-388.	1.9	58
39	<i>In vivo</i> profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile. British Journal of Pharmacology, 2015, 172, 532-548.	5.4	57
40	Quantitation of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Plasma and Cerebrospinal Fluid Using Solid-Phase Extraction and High-Performance Liquid Chromatography with Electrochemical Detection. Therapeutic Drug Monitoring, 1994, 16, 200-208.	2.0	55
41	High-throughput assay for simultaneous quantification of the plasma concentrations of morphine, fentanyl, midazolam and their major metabolites using automated SPE coupled to LC–MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 903, 126-133.	2.3	51
42	Hydromorphone-3-glucuronide: Biochemical synthesis and preliminary pharmacological evaluation. Life Sciences, 1998, 63, 401-411.	4.3	49
43	The cubane paradigm in bioactive molecule discovery: further scope, limitations and the cyclooctatetraene complement. Organic and Biomolecular Chemistry, 2019, 17, 6790-6798.	2.8	49
44	Characterization of non-conventional opioid binding sites in rat and human lung. European Journal of Pharmacology, 1994, 268, 247-255.	2.6	47
45	The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sciences, 1994, 54, 1229-1236.	4.3	46
46	SEX DIFFERENCES IN THE PHARMACOKINETICS, OXIDATIVE METABOLISM AND ORAL BIOAVAILABILITY OF OXYCODONE IN THE SPRAGUE-DAWLEY RAT. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 295-302.	1.9	46
47	Determination of the Serum Protein Binding of Oxycodone and Morphine Using Ultrafiltration. Therapeutic Drug Monitoring, 1993, 15, 440-447.	2.0	45
48	Studies on neurosteroids XIX. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 848, 188-199.	2.3	45
49	Analgesic Efficacy and Mode of Action of a Selective Small Molecule Angiotensin II Type 2 Receptor Antagonist in a Rat Model of Prostate Cancer-Induced Bone Pain. Pain Medicine, 2014, 15, 93-110.	1.9	45
50	Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. European Journal of Clinical Pharmacology, 1986, 31, 177-182.	1.9	44
51	Pain, analgesia and genetics. Journal of Pharmacy and Pharmacology, 2011, 63, 1387-1400.	2.4	43
52	Intraarticular and Periarticular Opioid Binding in Inflamed Tissue in Experimental Canine Arthritis. Anesthesia and Analgesia, 1999, 89, 409-415.	2.2	42
53	Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?. Journal of Antimicrobial Chemotherapy, 2013, 68, 726-727.	3.0	42
54	Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain. Pain, 2016, 157, S33-S41.	4.2	42

#	Article	IF	CITATIONS
55	Propranolol, Propranolol Glucuronide, and Naphthoxylactic Acid in Breast Milk and Plasma. Therapeutic Drug Monitoring, 1983, 5, 87-94.	2.0	41
56	Inhibition of acidâ€sensing ion channels by diminazene and APETx2 evoke partial and highly variable antihyperalgesia in a rat model of inflammatory pain. British Journal of Pharmacology, 2018, 175, 2204-2218.	5.4	39
57	Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology, 2013, 21, 339-363.	3.9	38
58	The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiology, 2013, 13, 7.	1.8	38
59	The Walker 256 Breast Cancer Cell- Induced Bone Pain Model in Rats. Frontiers in Pharmacology, 2016, 7, 286.	3.5	38
60	Simultaneous determination of morphine, oxycodone, morphine-3-glucuronide, and noroxycodone concentrations in rat serum by high performance liquid chromatography–electrospray ionization–tandem mass spectrometryâ~†. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 814, 241-249.	2.3	36
61	Sustained-release ketamine-loaded nanoparticles fabricated by sequential nanoprecipitation. International Journal of Pharmaceutics, 2020, 581, 119291.	5.2	36
62	Cerebrospinal Fluid and Plasma Concentrations of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Patients Before and After Initiation of Intracerebroventricular Morphine for Cancer Pain Management. Anesthesia and Analgesia, 1999, 88, 109-116.	2.2	34
63	Differences between and combinations of opioids re-visited. Current Opinion in Anaesthesiology, 2008, 21, 596-601.	2.0	34
64	Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. Pharmacology Biochemistry and Behavior, 2014, 126, 13-27.	2.9	34
65	Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. Angewandte Chemie, 2016, 128, 3644-3649.	2.0	34
66	Opioid analgesic prescribing and use - an audit of analgesic prescribing by general practitioners and The Multidisciplinary Pain Centre at Royal Brisbane Hospital. British Journal of Clinical Pharmacology, 2001, 52, 693-698.	2.4	33
67	Optimization and pharmacological characterization of a refined cisplatin-induced rat model of peripheral neuropathic pain. Behavioural Pharmacology, 2014, 25, 732-740.	1.7	32
68	Antiallodynic effects of alpha lipoic acid in an optimized <scp>RR</scp> â€ <scp>EAE</scp> mouse model of <scp>MS</scp> â€neuropathic pain are accompanied by attenuation of upregulated <scp>BDNF</scp> â€TrkBâ€ <scp>ERK</scp> signaling in the dorsal horn of the spinal cord. Pharmacology Research and Perspectives, 2015, 3, e00137.	2.4	32
69	In vivo High Angular Resolution Diffusion-Weighted Imaging of Mouse Brain at 16.4 Tesla. PLoS ONE, 2015, 10, e0130133.	2.5	32
70	Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opinion on Therapeutic Targets, 2015, 19, 25-35.	3.4	32
71	Pharmacogenetics of pain and analgesia. Clinical Genetics, 2012, 82, 321-330.	2.0	31
72	Comparative studies using the Morris water maze to assess spatial memory deficits in two transgenic mouse models of Alzheimer's disease. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 798-806.	1.9	31

#	Article	IF	CITATIONS
73	ANTINOCICEPTION VERSUS SERUM CONCENTRATION RELATIONSHIPS FOLLOWING ACUTE ADMINISTRATION OF INTRAVENOUS MORPHINE IN MALE AND FEMALE SPRAGUEâ€DAWLEY RATS: DIFFERENCES BETWEEN THE TAI FLICK AND HOT PLATE NOCICEPTIVE TESTS. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 20-28.	-1.9	29
74	Preliminary Study of the Plasma and Cerebrospinal Fluid Concentrations of IL-6 and IL-10 in Patients with Chronic Pain Receiving Intrathecal Opioid Infusions by Chronically Implanted Pump for Pain Management. Pain Medicine, 2010, 11, 550-561.	1.9	29
75	Lipo-Endomorphin-1 Derivatives with Systemic Activity against Neuropathic Pain without Producing Constipation. PLoS ONE, 2012, 7, e41909.	2.5	29
76	The effect of 1Âmg folic acid supplementation on clinical outcomes in female migraine with aura patients. Journal of Headache and Pain, 2016, 17, 60.	6.0	29
77	Quantitation of Oxycodone in Human Plasma Using High-Performance Liquid Chromatography with Electrochemical Detection. Therapeutic Drug Monitoring, 1991, 13, 126-130.	2.0	27
78	Brain region-specific studies of the excitatory behavioral effects of morphine-3-glucuronide. Life Sciences, 1999, 65, 225-236.	4.3	27
79	Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain. Frontiers in Behavioral Neuroscience, 2016, 10, 88.	2.0	27
80	A Sensitive Liquid Chromatographic Assay for Plasma Aspirin and Salicylate Concentrations After Low Doses of Aspirin. Therapeutic Drug Monitoring, 1985, 7, 216-221.	2.0	26
81	Deletion of guanine nucleotide binding protein αz subunit in mice induces a gene dose dependent tolerance to morphine. Neuropharmacology, 2004, 46, 836-846.	4.1	26
82	Longitudinal Study of Painful Diabetic Neuropathy in the Zucker Diabetic Fatty Rat Model of Type 2 Diabetes: Impaired Basal G-Protein Activity Appears to Underpin Marked Morphine Hyposensitivity at 6 Months. Pain Medicine, 2011, 12, 437-450.	1.9	26
83	Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. Pharmacology Biochemistry and Behavior, 2013, 106, 33-46.	2.9	26
84	Effects of long-term opioid analgesics on cognitive performance and plasma cytokine concentrations in patients with chronic low back pain: a cross-sectional pilot study. Pain Reports, 2018, 3, e669.	2.7	26
85	Quantitative autoradiography of peripheral opioid binding sites in rat lung. European Journal of Pharmacology, 1996, 310, 47-53.	3.5	25
86	Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions. British Journal of Clinical Pharmacology, 2005, 59, 524-535.	2.4	25
87	Cyclooctatetraene: A Bioactive Cubane Paradigm Complement. Chemistry - A European Journal, 2019, 25, 2729-2734.	3.3	24
88	Countering opioid-induced respiratory depression by non-opioids that are respiratory stimulants. F1000Research, 2020, 9, 91.	1.6	24
89	Propranolol in Pregnancy Three Year Prospective Study. Clinical and Experimental Hypertension Part B, Hypertension in Pregnancy, 1983, 2, 341-350.	0.2	23
90	Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy. Behavioural Pharmacology, 2014, 25, 137-146.	1.7	23

#	Article	IF	CITATIONS
91	Theoretical and practical applications of the intracerebroventricular route for CSF sampling and drug administration in CNS drug discovery research: A mini review. Journal of Neuroscience Methods, 2014, 233, 166-171.	2.5	23
92	Novel Polymeric Bioerodable Microparticles for Prolonged-Release Intrathecal Delivery of Analgesic Agents for Relief of Intractable Cancer-Related Pain. Journal of Pharmaceutical Sciences, 2015, 104, 2334-2344.	3.3	23
93	Solid-phase extraction method with high-performance liquid chromatography and electrochemical detection for the quantitative analysis of oxycodone in human plasma. Biomedical Applications, 1998, 712, 169-175.	1.7	22
94	Comparison of the Pharmacokinetics of Oxycodone and Noroxycodone in Male Dark Agouti and Sprague–Dawley Rats: Influence of Streptozotocin-Induced Diabetes. Pharmaceutical Research, 2005, 22, 1489-1498.	3.5	22
95	Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography–electrospray ionization–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2007. 848. 264-270.	2.3	22
96	Measurement of intracellular Ca2+ in cultured rat embryonic hippocampal neurons using a fluorescence microplate reader: potential application to biomolecular screening. Journal of Pharmacological and Toxicological Methods, 2004, 49, 81-87.	0.7	21
97	Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC–MS/MS) for determination of risedronate concentrations in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2012. 881-882. 34-41.	2.3	21
98	Fully validated LC–MS/MS method for quantification of homocysteine concentrations in samples of human serum: A new approach. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 972, 14-21.	2.3	21
99	In vitro methods for hazard assessment of industrial chemicals – opportunities and challenges. Frontiers in Pharmacology, 2015, 6, 94.	3.5	20
100	Pregabalin for the treatment of fibromyalgia. Expert Opinion on Pharmacotherapy, 2012, 13, 1527-1533.	1.8	19
101	Chronic low back pain: a mini-review on pharmacological management and pathophysiological insights from clinical and pre-clinical data. Inflammopharmacology, 2018, 26, 881-898.	3.9	19
102	Bioavailability and pharmacokinetics of phenytoin during pregnancy. European Journal of Clinical Pharmacology, 1984, 27, 105-110.	1.9	19
103	Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2012, 14, 105-11.	0.1	19
104	Pharmacokinetics of prazepam in man. European Journal of Clinical Pharmacology, 1979, 16, 141-147.	1.9	17
105	Intraarticular and Periarticular Opioid Binding in Inflamed Tissue in Experimental Canine Arthritis. Anesthesia and Analgesia, 1999, 89, 409-415.	2.2	17
106	Peripherally acting novel lipo-endomorphin-1 peptides in neuropathic pain without producing constipation. Bioorganic and Medicinal Chemistry, 2013, 21, 1898-1904.	3.0	17
107	The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain. Frontiers in Pharmacology, 2018, 9, 495.	3.5	17
108	Attenuation of the Infiltration of Angiotensin II Expressing CD3+ T-Cells and the Modulation of Nerve Growth Factor in Lumbar Dorsal Root Ganglia – A Possible Mechanism Underpinning Analgesia Produced by EMA300, An Angiotensin II Type 2 (AT2) Receptor Antagonist. Frontiers in Molecular Neuroscience, 2017, 10, 389.	2.9	16

#	Article	IF	CITATIONS
109	Journey to the Market: The Evolution of Biodegradable Drug Delivery Systems. Applied Sciences (Switzerland), 2022, 12, 935.	2.5	16
110	Comparative studies of the neuro-excitatory behavioural effects of morphine-3-glucuronide and dynorphin A(2-17) following spinal and supraspinal routes of administration. Pharmacology Biochemistry and Behavior, 2009, 93, 498-505.	2.9	15
111	Optimization and In Vivo Profiling of a Refined Rat Model of Walker 256 Breast Cancer Cell-Induced Bone Pain Using Behavioral, Radiological, Histological, Immunohistochemical and Pharmacological Methods. Frontiers in Pharmacology, 2017, 8, 442.	3.5	15
112	Metabolism of propranolol in the human maternal-placental-foetal unit. European Journal of Clinical Pharmacology, 1983, 24, 727-732.	1.9	14
113	Morphine has a Dual Concentration-dependent Effect on K+-evoked Substance P Release from Rat Peripheral Airways. Pulmonary Pharmacology and Therapeutics, 1997, 10, 215-221.	2.6	14
114	The furoxan nitric oxide donor, <scp>PRG</scp> 150, evokes doseâ€dependent analgesia in a rat model of painful diabetic neuropathy. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 921-929.	1.9	14
115	Topical Application of a Novel Oxycodone Gel Formulation (Tocopheryl Phosphate Mixture) in a Rat Model of Peripheral Inflammatory Pain Produces Localized Pain Relief Without Significant Systemic Exposure. Journal of Pharmaceutical Sciences, 2015, 104, 2388-2396.	3.3	14
116	Establishment and Characterization of a Novel Rat Model of Mechanical Low Back Pain Using Behavioral, Pharmacologic and Histologic Methods. Frontiers in Pharmacology, 2017, 8, 493.	3.5	14
117	Effects of morphine-3-glucuronide and morphine on the K+-evoked release of [3H]-glutamic acid and [14C]-gamma-aminobutyric acid from rat brain synaptosomes. Life Sciences, 1995, 58, 447-454.	4.3	13
118	Insulin Implants Prevent the Temporal Development of Mechanical Allodynia and Opioid Hyposensitivity for 24-Wks in Streptozotocin (STZ)-Diabetic Wistar Rats. Pain Medicine, 2011, 12, 782-793.	1.9	13
119	Angiotensin II Type 2â€Receptor: New Clinically Validated Target in the Treatment of Neuropathic Pain. Clinical Pharmacology and Therapeutics, 2015, 97, 128-130.	4.7	13
120	Sustained-Release Hydromorphone Microparticles Produced by Supercritical Fluid Polymer Encapsulation. Journal of Pharmaceutical Sciences, 2019, 108, 811-814.	3.3	13
121	Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources. Journal of Medicinal Chemistry, 2022, 65, 1612-1661.	6.4	13
122	Chronic propranolol administration during pregnancy. European Journal of Clinical Pharmacology, 1983, 25, 481-490.	1.9	12
123	A simple, low-cost, remote fiber-optic micro volume fluorescence flowcell for capillary flow-injection analysis. Analytical and Bioanalytical Chemistry, 2002, 374, 385-389.	3.7	12
124	Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity. Bioorganic and Medicinal Chemistry, 2014, 22, 2208-2219.	3.0	12
125	Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine. European Journal of Pharmacology, 2020, 871, 172918.	3.5	12
126	<i>In Vitro</i> Metabolic Stability and <i>in Vivo</i> Biodistribution of 3-Methyl-4-furoxancarbaldehyde Using PET Imaging in Rats. ACS Medicinal Chemistry Letters, 2016, 7, 563-567.	2.8	11

#	Article	IF	CITATIONS
127	Evaluation of a High-Throughput Peptide Reactivity Format Assay for Assessment of the Skin Sensitization Potential of Chemicals. Frontiers in Pharmacology, 2016, 7, 53.	3.5	10
128	Investigation of the antinociceptive efficacy and relative potency of extended duration injectable 3-acylmorphine-6-sulfate prodrugs in rats. International Journal of Pharmaceutics, 1998, 163, 191-201.	5.2	9
129	Cerebrospinal Fluid and Plasma Concentrations of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Patients Before and After Initiation of Intracerebroventricular Morphine for Cancer Pain Management. Anesthesia and Analgesia, 1999, 88, 109-116.	2.2	9
130	A novel fully validated LC–MS/MS method for quantification of pyridoxal-5′-phosphate concentrations in samples of human whole blood. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1000, 77-83.	2.3	9
131	Use of Microfluidics to Fabricate Bioerodable Lipid Hybrid Nanoparticles Containing Hydromorphone or Ketamine for the Relief of Intractable Pain. Pharmaceutical Research, 2020, 37, 211.	3.5	9
132	Simple and Reliable Determination of Bromazepam in Human Plasma by High-Performance Liquid Chromatography. Analytica Chimica Acta, 1985, 177, 267-271.	5.4	8
133	Oxycodone has a distinctly different pharmacology from morphine. European Journal of Pain, 2001, 5, 135-136.	2.8	8
134	Formulation of Bioerodible Ketamine Microparticles as an Analgesic Adjuvant Treatment Produced by Supercritical Fluid Polymer Encapsulation. Pharmaceutics, 2018, 10, 264.	4.5	8
135	Comparative analgesic efficacy of pregabalin administered according to either a prevention protocol or an intervention protocol in rats with cisplatinâ€induced peripheral neuropathy. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 1067-1075.	1.9	8
136	J-2156, a somatostatin receptor type 4 agonist, alleviates mechanical hyperalgesia in a rat model of chronic low back pain. Biomedicine and Pharmacotherapy, 2019, 117, 109056.	5.6	8
137	Synthesis and Biological Evaluation of Fentanyl Analogues Modified at Phenyl Groups with Alkyls. ACS Chemical Neuroscience, 2019, 10, 201-208.	3.5	8
138	In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the β-arrestin2 recruitment assay: No two ligands have the same profile. European Journal of Pharmacology, 2020, 872, 172947.	3.5	8
139	Improved One-Step Solid-Phase Extraction Method for Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide From Plasma and Quantitation Using High-Performance Liquid Chromatography With Electrochemical Detection. Therapeutic Drug Monitoring, 1998, 20, 215-218.	2.0	8
140	Biochemical synthesis, purification and preliminary pharmacological evaluation of normorphine-3-glucuronide. Life Sciences, 1997, 61, 95-104.	4.3	7
141	Bioerodable Ketamine-Loaded Microparticles Fabricated Using Dissolvable Hydrogel Template Technology. Journal of Pharmaceutical Sciences, 2019, 108, 1220-1226.	3.3	7
142	Oxycodone's Mechanism of Action and Potency Differences after Spinal and Systemic Routes of Administration. Anesthesiology, 2007, 106, 1063-1064.	2.5	7
143	The role of morphine-6-glucuronide (M6G) in pain control. Pain Reviews, 2001, 8, 171-191.	0.0	6
144	Co-administration of oxycodone and morphine and analgesic synergy re-examined. British Journal of Clinical Pharmacology, 2005, 59, 486-487.	2.4	6

#	Article	IF	CITATIONS
145	High-throughput assay for quantification of the plasma concentrations of thiopental using automated solid phase extraction (SPE) directly coupled to LC–MS/MS instrumentation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1038, 80-87.	2.3	6
146	Morphine hyposensitivity in streptozotocinâ€diabetic rats: Reversal by dietary <scp>l</scp> â€arginine treatment. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 42-49.	1.9	6
147	An improved liquid chromatography tandem mass spectrometry (LC–MS/MS) method for quantification of dexmedetomidine concentrations in samples of human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1073, 118-122.	2.3	6
148	The unsteady model. European Journal of Clinical Pharmacology, 1981, 20, 387-398.	1.9	5
149	STUDIES WITH KETAMINE AND ALFENTANIL FOLLOWING FREUND'S COMPLETE ADJUVANT-INDUCED INFLAMMATION IN RATS. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 414-420.	1.9	5
150	An improved LC–MS/MS method for simultaneous evaluation of CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activity. Bioanalysis, 2018, 10, 1577-1590.	1.5	5
151	In vivo profiling of four centrally administered opioids for antinociception, constipation and respiratory depression: Betweenâ€colony differences in Sprague Dawley rats. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 1056-1066.	1.9	5
152	Nitric oxide modulates μâ€opioid receptor function in vitro. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 676-685.	1.9	5
153	Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain. Pharmacological Reports, 2020, 72, 1418-1425.	3.3	5
154	Assessment of the Anti-Allodynic and Anti-Hyperalgesic Efficacy of a Glycine Transporter 2 Inhibitor Relative to Pregabalin, Duloxetine and Indomethacin in a Rat Model of Cisplatin-Induced Peripheral Neuropathy. Biomolecules, 2021, 11, 940.	4.0	5
155	Pharmacological characterization of the chronic phase of the monoiodoacetateâ€induced rat model of osteoarthritis pain in the knee joint. Clinical and Experimental Pharmacology and Physiology, 2021, 48, 1515-1522.	1.9	5
156	Novel Source of Ubiquitous Phthalates as Analytical Contaminant. Journal of Pharmaceutical Sciences, 1981, 70, 346-347.	3.3	3
157	The Neuroexcitatory Morphine Metabolite, Morphine-3-glucuronide (M3G), is not Neurotoxic in Primary Cultures of either Hippocampal or Cerebellar Granule Neurones. Basic and Clinical Pharmacology and Toxicology, 2003, 93, 197-200.	0.0	3
158	Sustained release ketamine-loaded porous silicon-PLGA microparticles prepared by an optimized supercritical CO2 process. Drug Delivery and Translational Research, 2021, , 1.	5.8	3
159	Optimisation of a Microfluidic Method for the Delivery of a Small Peptide. Pharmaceutics, 2021, 13, 1505.	4.5	3
160	Design, synthesis and evaluation of alpha lipoic acid derivatives to treat multiple sclerosis-associated central neuropathic pain. Bioorganic and Medicinal Chemistry, 2022, 69, 116889.	3.0	3
161	Effect of cardiopulmonary bypass on cytochrome P450 enzyme activity: implications for pharmacotherapy. Drug Metabolism Reviews, 2018, 50, 109-124.	3.6	2
162	Transcriptomic characterisation of the optimised rat model of Walker 256 breast cancer cellâ€induced bone pain. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 1201-1215.	1.9	2

#	Article	IF	CITATIONS
163	Establishment and characterisation of a stavudine (d4T)-induced rat model of antiretroviral toxic neuropathy (ATN) using behavioural and pharmacological methods. Inflammopharmacology, 2019, 27, 387-396.	3.9	2
164	Pharmacokinetics and Pharmacodynamics of Oxycodone When Given Intravenously and Rectally to Adult Patients with Cancer Pain. Anesthesia and Analgesia, 1995, 80, 296-302.	2.2	1
165	Clinical Pharmacology and Adverse Effects. , 1998, , 188-211.		1
166	Current developments in MRI for assessing rodent models of multiple sclerosis. Future Neurology, 2014, 9, 487-511.	0.5	1
167	Frontispiece: Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. Angewandte Chemie - International Edition, 2016, 55, .	13.8	1
168	Assessment of the antiâ€hyperalgesic efficacy of Jâ€2156, relative to clinically available analgesic/adjuvant agents in a rat model of mild to moderate chronic mechanical low back pain (LBP). Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1912-1922.	1.9	1
169	Characterisation of a rat model of mechanical low back pain at an advanced stage using immunohistochemical methods. Clinical and Experimental Pharmacology and Physiology, 2021, 48, 96-106.	1.9	1
170	Comments on Goucke et al., Pain, 56 (1994) 145–149. Pain, 1994, 59, 155-156.	4.2	0
171	Comment on "protective arms of the reninâ€angiotensin system in neurological diseaseâ€. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 838-838.	1.9	0
172	Frontispiz: Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. Angewandte Chemie, 2016, 128, .	2.0	0
173	Study Protocol for a Pilot, Open-Label, Prospective, and Observational Study to Evaluate the Pharmacokinetics of Drugs Administered to Patients during Extracorporeal Circulation; Potential of In Vivo Cytochrome P450 Phenotyping to Optimise Pharmacotherapy. Methods and Protocols, 2019, 2, 38.	2.0	0
174	Comparative studies of glial fibrillary acidic protein and brainâ€derived neurotrophic factor expression in two transgenic mouse models of Alzheimer's disease. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1740-1750.	1.9	0
175	Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice. Drug Delivery and Translational Research, 2021, , 1.	5.8	0